Complement system modulation: targeting complement proteins (e.g., C3 and C5 inhibitors) is a promising approach to limit excessive immune activation, particularly in conditions like multiple sclerosis (Saez-Calveras and Stuve, 2022; Zelek and Morgan, 2022). Here, C3 is linked to multiple sclerosis.